{"protocolSection":{"identificationModule":{"nctId":"NCT06834165","orgStudyIdInfo":{"id":"EPI R01"},"organization":{"fullName":"ARS Pharmaceuticals, Inc.","class":"INDUSTRY"},"briefTitle":"Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy","officialTitle":"A Phase IV Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy"},"statusModule":{"statusVerifiedDate":"2025-10","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-05-20","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-04","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-06","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-02-18","studyFirstSubmitQcDate":"2025-02-18","studyFirstPostDateStruct":{"date":"2025-02-19","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-10-24","lastUpdatePostDateStruct":{"date":"2025-10-27","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"ARS Pharmaceuticals, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The study is to assess the safety of neffy or IM Adrenalin in patients who are experiencing allergic reactions after an OFC, allergen Immunotherapy (AIT), or other allergy challenge that may require epinephrine intervention."},"conditionsModule":{"conditions":["Allergic Reactions"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":600,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Neffy","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Neffy"]},{"label":"IM adrenaline","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Adrenaline"]}],"interventions":[{"type":"DRUG","name":"Neffy","description":"Epinephrine nasal spray","armGroupLabels":["Neffy"]},{"type":"DRUG","name":"Adrenaline","description":"Epinephrine injection","armGroupLabels":["IM adrenaline"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"AEs after epinephrine treatment within 2 hours","timeFrame":"2 hours"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Is a patient 4 years old or greater, inclusive, who are scheduled to undergo OFC, AIT, or other relevant allergy challenge.\n* Has body weight 15 kg or greater at the time of allergy challenge.\n* Is willing and able to provide written informed consent prior to participating in the study. In the case of minors (\\<18 years old), assent can be obtained from his/her legal representative, and as much possible from the patient himself/herself.\n* Patient experiences an allergic reaction that, in the opinion of the Investigator, requires treatment with epinephrine via neffy or IM Adrenalin.\n\nExclusion Criteria:\n\n\\- Has any clinically significant medical condition that precludes treatment with epinephrine as assessed by the Investigator.","healthyVolunteers":false,"sex":"ALL","minimumAge":"4 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Osnat Ehrman, MSc.","role":"CONTACT","phone":"952.334.5797","email":"osnate@pacificlinkconsulting.com"}],"locations":[{"facility":"Orso Health, Inc.","status":"RECRUITING","city":"La Jolla","state":"California","zip":"92037","country":"United States","contacts":[{"name":"Investigator, MD","role":"CONTACT","phone":"858-260-2977","email":"adoroudchi@modena-health.com"},{"name":"Ali Doroudchi, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":32.84727,"lon":-117.2742}},{"facility":"Cincinnati Children's Hospital Medical Center","status":"RECRUITING","city":"Cincinnati","state":"Ohio","zip":"45229","country":"United States","contacts":[{"name":"Investigator, MD","role":"CONTACT","phone":"513-517-1179","email":"Yasmin.hassoun@cchmc.org"},{"name":"Yasmin Hassoun, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":39.12711,"lon":-84.51439}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D006967","term":"Hypersensitivity"}],"ancestors":[{"id":"D007154","term":"Immune System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D004837","term":"Epinephrine"}],"ancestors":[{"id":"D004983","term":"Ethanolamines"},{"id":"D000605","term":"Amino Alcohols"},{"id":"D000438","term":"Alcohols"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D000588","term":"Amines"},{"id":"D015306","term":"Biogenic Monoamines"},{"id":"D001679","term":"Biogenic Amines"},{"id":"D002395","term":"Catecholamines"},{"id":"D002396","term":"Catechols"},{"id":"D010636","term":"Phenols"},{"id":"D001555","term":"Benzene Derivatives"},{"id":"D006841","term":"Hydrocarbons, Aromatic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"}]}},"hasResults":false}